(Q27851668)

1

0 references

Jennifer E Quinn

2

0 references

Caroline O Michie

3

0 references

Eamonn J O'Brien

4

0 references

Perry Maxwell

6

0 references

Elisabeth Lamers

7

0 references

Tong F Lioe

8

0 references

Alistair R W Williams

9

0 references

Richard D Kennedy

10

0 references

Charlie Gourley

11

0 references

D Paul Harkin

12

0 references

language of work or name

English

0 references

publication date

December 2011

0 references

published in

Gynecologic Oncology

0 references

volume

123

0 references

issue

3

0 references

page(s)

492-8

0 references

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Frequency of BRCA1 dysfunction in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Use of a BRCA1 peptide validates MS110 as a BRCA1-specific antibody in immunohistochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Improved survival in women with BRCA-associated ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Prognostic impact ofBRCA1 pathogenic andBRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Reduction of BRCA1 expression in sporadic ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

A mouse model for the molecular characterization of brca1-associated ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

BRCA1 and implications for response to chemotherapy in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.017